IMMUCELL CORP (ICCC) Fundamental Analysis & Valuation

NASDAQ:ICCC • US4525253062

Current stock price

7.19 USD
+0.81 (+12.7%)
Last:

This ICCC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. ICCC Profitability Analysis

1.1 Basic Checks

  • ICCC had negative earnings in the past year.
  • ICCC had a positive operating cash flow in the past year.
  • In the past 5 years ICCC always reported negative net income.
  • In multiple years ICCC reported negative operating cash flow during the last 5 years.
ICCC Yearly Net Income VS EBIT VS OCF VS FCFICCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M

1.2 Ratios

  • ICCC's Return On Assets of 5.08% is amongst the best of the industry. ICCC outperforms 90.91% of its industry peers.
  • ICCC has a Return On Equity of 7.80%. This is amongst the best in the industry. ICCC outperforms 91.88% of its industry peers.
  • ICCC has a Return On Invested Capital of 4.41%. This is amongst the best in the industry. ICCC outperforms 89.94% of its industry peers.
Industry RankSector Rank
ROA 5.08%
ROE 7.8%
ROIC 4.41%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ICCC Yearly ROA, ROE, ROICICCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

1.3 Margins

  • ICCC's Profit Margin of 8.37% is amongst the best of the industry. ICCC outperforms 90.14% of its industry peers.
  • ICCC has a better Operating Margin (8.39%) than 89.56% of its industry peers.
  • ICCC has a better Gross Margin (40.93%) than 73.50% of its industry peers.
  • In the last couple of years the Gross Margin of ICCC has declined.
Industry RankSector Rank
OM 8.39%
PM (TTM) 8.37%
GM 40.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-1.53%
ICCC Yearly Profit, Operating, Gross MarginsICCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ICCC Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ICCC is destroying value.
  • There is no outstanding debt for ICCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ICCC Yearly Shares OutstandingICCC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ICCC Yearly Total Debt VS Total AssetsICCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • An Altman-Z score of 3.18 indicates that ICCC is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ICCC (3.18) is better than 68.86% of its industry peers.
  • ICCC has a debt to FCF ratio of 13.27. This is a negative value and a sign of low solvency as ICCC would need 13.27 years to pay back of all of its debts.
  • ICCC's Debt to FCF ratio of 13.27 is amongst the best of the industry. ICCC outperforms 90.14% of its industry peers.
  • A Debt/Equity ratio of 0.27 indicates that ICCC is not too dependend on debt financing.
  • ICCC has a Debt to Equity ratio of 0.27. This is in the lower half of the industry: ICCC underperforms 67.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 13.27
Altman-Z 3.18
ROIC/WACC0.49
WACC8.93%
ICCC Yearly LT Debt VS Equity VS FCFICCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 4.21 indicates that ICCC has no problem at all paying its short term obligations.
  • The Current ratio of ICCC (4.21) is comparable to the rest of the industry.
  • A Quick Ratio of 1.76 indicates that ICCC should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.76, ICCC is not doing good in the industry: 78.14% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 4.21
Quick Ratio 1.76
ICCC Yearly Current Assets VS Current LiabilitesICCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. ICCC Growth Analysis

3.1 Past

  • ICCC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.07%, which is quite impressive.
  • ICCC shows a small growth in Revenue. In the last year, the Revenue has grown by 4.34%.
  • ICCC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.50% yearly.
EPS 1Y (TTM)62.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-616.67%
Revenue 1Y (TTM)4.34%
Revenue growth 3Y14.18%
Revenue growth 5Y12.5%
Sales Q2Q%-1.55%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ICCC Yearly Revenue VS EstimatesICCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
ICCC Yearly EPS VS EstimatesICCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2023 2024 2025 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

2

4. ICCC Valuation Analysis

4.1 Price/Earnings Ratio

  • ICCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICCC Price Earnings VS Forward Price EarningsICCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • ICCC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ICCC is cheaper than 94.78% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, ICCC is valued cheaply inside the industry as 91.49% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 90.96
EV/EBITDA 14.06
ICCC Per share dataICCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ICCC Dividend Analysis

5.1 Amount

  • No dividends for ICCC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ICCC Fundamentals: All Metrics, Ratios and Statistics

IMMUCELL CORP

NASDAQ:ICCC (4/9/2026, 8:00:02 PM)

7.19

+0.81 (+12.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04
Earnings (Next)05-12
Inst Owners20.3%
Inst Owner Change0%
Ins Owners26.45%
Ins Owner Change0.57%
Market Cap65.07M
Revenue(TTM)27.64M
Net Income(TTM)2.32M
Analysts82.86
Price TargetN/A
Short Float %0.45%
Short Ratio1.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.34
P/FCF 90.96
P/OCF 32.7
P/B 2.18
P/tB 2.19
EV/EBITDA 14.06
EPS(TTM)-0.11
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY1.1%
OCF(TTM)0.22
OCFY3.06%
SpS3.07
BVpS3.29
TBVpS3.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 5.08%
ROE 7.8%
ROCE 5.58%
ROIC 4.41%
ROICexc 4.86%
ROICexgc 4.87%
OM 8.39%
PM (TTM) 8.37%
GM 40.93%
FCFM 2.58%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-1.53%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 13.27
Debt/EBITDA 1.57
Cap/Depr 47.25%
Cap/Sales 4.59%
Interest Coverage 5.01
Cash Conversion 39.59%
Profit Quality 30.79%
Current Ratio 4.21
Quick Ratio 1.76
Altman-Z 3.18
F-Score7
WACC8.93%
ROIC/WACC0.49
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-616.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.34%
Revenue growth 3Y14.18%
Revenue growth 5Y12.5%
Sales Q2Q%-1.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y171.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y200%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y647.83%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUCELL CORP / ICCC Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IMMUCELL CORP?

ChartMill assigns a fundamental rating of 4 / 10 to ICCC.


What is the valuation status of IMMUCELL CORP (ICCC) stock?

ChartMill assigns a valuation rating of 2 / 10 to IMMUCELL CORP (ICCC). This can be considered as Overvalued.


What is the profitability of ICCC stock?

IMMUCELL CORP (ICCC) has a profitability rating of 5 / 10.


How financially healthy is IMMUCELL CORP?

The financial health rating of IMMUCELL CORP (ICCC) is 5 / 10.